과제정보
This study was supported by a grant from the Korea Institute of Radiological and Medical Sciences (KIRAMS), by the Ministry of Science and ICT (MSIT), the Republic of Korea (No. 50536-2021), and by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2020R1A2C2008618).
참고문헌
- Blandini F, Porter RH, Greenamyre IT. Glutamate and Parkinson's disease. MolNeurobiol1996;12:73-94.
- McEntee WJ, Crook TH. Glutamate: its role in learning, memory, and the aging brain. Psychophannacology (Berl) 1993;111:391-401. https://doi.org/10.1007/BF02253527
- Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr 2000; 130 (4S Suppl): 1007S-15S. https://doi.org/10.1093/jn/130.4.1007S
- Jewett BE, Sharma S. Physiology, GABA. In StatPearls, Treasure Island (FL), 2021.
- Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch 2010;460:525-42. https://doi.org/10.1007/s00424-010-0809-1
- Carroll FI. Antagonists at metabotropic glutamate receptor subtype 5 : structure activity relationships and therapeutic potential for addiction. Ann NY Acad Sci 2008;1141:221-32. https://doi.org/10.1196/annals.1441.015
- Crupi R, Impellizzeri D, Cuzzocrea S. Role of Metabotropic Glutamate Receptors in Neurological Disorders. Front Mal Neurosci 2019; 12:20.
- Moghaddam B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 2004;174:39-44. https://doi.org/10.1007/s00213-004-1792-z
- Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, Varney MA, Johnson EC, Hess SD, Rao SP, Sacaan AI, Santori EM, Velicelebi G, Kuhn R. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 1999;38:1493-503. https://doi.org/10.1016/S0028-3908(99)00082-9
- Varney MA, Cosford ND, Jachec C, Rao SP, Sacaan A, Lin FF, Bleicher L, Santori E M, Flor PJ, Allgeier H, Gasparini F, Kuhn R, Hess SD, Velicelebi G, Johnson EC. SIB-1757 and SIB-1893 : selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J Pharmacol Exp Ther 1999;290:170-81.
- Hamill TG, Krause S, Ryan C, Bonnefous C, Govek S, Seiders TJ, Cosford ND, Roppe, J, Kamenecka T, Patel S, Gibson RE, Sanabria S, Riffel K, Eng W, King C, Yang X, Green MD, O'Malley SS, Hargreaves R, Bums HD. Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. Synapse 2005;56:205-16. https://doi.org/10.1002/syn.20147
- Wong DF, Waterhouse R, Kuwabara H, Kim J, Brasic JR, Chamroonrat W, Stabins M, Holt DP, Dannals RF, Hamill TG, Mozley PD. 18F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry. J Nucl Med 2013;54:388-96. https://doi.org/10.2967/jnumed.112.107995
- Lim K, Labaree D, Li S, Huang Y. Preparation of the metabotropic glutamate receptor 5 (mGluR5) PET tracer [18F]FPEB for human use: An automated radiosynthesis and a novel one-pot synthesis of its radiolabeling precursor. Appl Radiat Isot 2014;94:349-54. https://doi.org/10.1016/j.apradiso.2014.09.006
- Stephenson NA, Holland JP, Kassenbrock A, Yokell DL, Livni E, Liang SH, Vasdev N. Iodonium ylide-mediated radiofluorination of 18F-FPEB And validation for human use. J Nucl Med 2015;56:489-92. https://doi.org/10.2967/jnumed.114.151332
- Varlow C, Murrell E, Holland JP, Kassenbrock A, Shannon W, Liang SH, Vasdev N, Stephenson NA. Revisiting the Radiosynthesis of [18F]FPEB and Preliminary PET Imaging in a Mouse Model of Alzheimer's Disease. Molecules 2020;25:982.